Glucocorticoid-Induced Ocular Hypertension: Origins and New Approaches to Minimize.
Glucocorticoid-Induced Ocular Hypertension: Origins and New Approaches to Minimize.
复制标题
糖皮质激素引起的高眼压：起源和最小化的新方法。
DOI：
10.1080/17469899.2020.1762488
复制
发表时间：
2020
影响因子：
0.7
通讯作者：
Clark,AbbotF
中科院分区：
文献类型：
--
作者：
Yorio,Thomas;Patel,GaurangC;Clark,AbbotF
糖皮质激素(Garcocorticoid，GCs)具有独特的抗炎和免疫抑制作用，是治疗炎症性疾病的常用药物之一。它们经常被临床用于治疗炎症性眼病，如葡萄膜炎、视神经炎、结膜炎、角膜炎和其他，但经常伴随副作用，如可能威胁视力的高眼压。该综述将集中于GCs复杂的分子作用机制，涉及反式激活和反式抑制，以及它们的治疗使用，可导致显著的全身副作用，特别是可导致青光眼的高眼压。专家意见虽然我们仍不清楚GC诱导的高眼压的所有机制，但有潜在的新疗法正在开发中，可以将一些抗炎治疗效果与其高眼压副作用分开。这篇综述提供了对这些方法的一些见解。
IntroductionGlucocorticoids (GCs) have unique actions in their combined anti-inflammatory and immunosuppressive activities and are among the most commonly prescribed drugs, particularly for inflammatory conditions. They are often used clinically to treat inflammatory eye diseases like uveitis, optic neuritis, conjunctivitis, keratitis, and others, but are often accompanied by side effects, like ocular hypertension that can be vision threatening.Areas coveredThe review will focus on the complex molecular mechanism of action of GCs that involve both transactivation and transrepression and their use therapeutically that can cause significant systemic side effects, particularly ocular hypertension that can lead to glaucoma.Expert OpinionWhile we are still unclear as to all the mechanisms responsible for GC-induced ocular hypertension, however, there are potential novel therapies that are in development that can separate some of the anti-inflammatory therapeutic efficacy from their ocular hypertension side effect. This review provides some insight into these approaches.